LZAGF - MaxCyte: Enabling Next-Generation Cell Based Therapies Attractive Risk-Return Profile
- MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology.
- The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100% gross margins) are set to account for a larger percentage of revenues over time.
- MXCT offers an attractive risk/return profile for investors that want exposure to the cell and gene therapy area, but do not have the risk appetite to invest directly in the space.
For further details see:
MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile